Novel theories of harm spark legal uncertainty for pharmaceutical deal reviews
Introduction As competition authorities’ review of pharmaceutical deals continues to expand, there is ongoing attention to whether the existing toolbox for identifying and remedying competition issues suffices. For example, in March 2021, several …